Our columnist on four stellar new releases. Alida Becker was an editor at the Book Review for 30 years. She was the first ...

When Deni Ellis Béchard started writing his new novel five years ago, the concept seemed far-fetched — even fanciful. These ...

I'm fascinated by the things that are universal, that leave a stamp on our identities,” Charmaine Wilkerson tells PEOPLE ...

Jurassic World Rebirth has a sequence from the first Jurassic Park novel that didn’t make it into 1993’s seminal Jurassic ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $93.07 which represents a slight increase of $0.15 or 0.16% from the prior close of $92.92. The stock opened at $92.36 and ...

Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $92.92 which represents a decrease of $-0.12 or -0.13% from the prior close of $93.04. The stock opened at $93.03 and touched a low of ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) on January 21 and set a price target ...

Margaret Atwood’s The Handmaid’s Tale has once again captured the public’s imagination, resonating with readers and viewers ...

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

Hilary Mantel’s “The Mirror and the Light,” a new “Bridget Jones” and Michael Bond’s Paddington Bear series are some of this ...

Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune diseases, a continued appetite for next-generation obesity drugs and an increased ...